Q2 EPS Forecast for BriaCell Therapeutics Raised by Analyst

BriaCell Therapeutics Corp. (TSE:BCT) – Research analysts at HC Wainwright increased their Q2 2025 earnings estimates for BriaCell Therapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.83) per share for the quarter, up from their prior estimate of ($5.70). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($3.57) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.01) EPS and FY2029 earnings at ($0.35) EPS.

BriaCell Therapeutics Stock Up 8.5 %

Shares of BCT stock opened at C$6.48 on Wednesday. The firm has a 50 day moving average of C$1.66 and a two-hundred day moving average of C$1.24. The stock has a market capitalization of C$232.24 million, a PE ratio of -12.96 and a beta of 1.83. BriaCell Therapeutics has a 52 week low of C$5.68 and a 52 week high of C$86.85.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.